(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.
Adial Pharmaceuticals's earnings in 2026 is -$57,801,206.On average, 5 Wall Street analysts forecast ADIL's earnings for 2026 to be -$10,302,942, with the lowest ADIL earnings forecast at -$18,245,209, and the highest ADIL earnings forecast at -$2,812,328. On average, 4 Wall Street analysts forecast ADIL's earnings for 2027 to be -$4,097,964, with the lowest ADIL earnings forecast at -$6,407,697, and the highest ADIL earnings forecast at -$1,571,595.
In 2028, ADIL is forecast to generate -$4,580,077 in earnings, with the lowest earnings forecast at -$4,400,466 and the highest earnings forecast at -$4,714,785.